BioPharmSignal logoBioPharmSignal

Biotech News

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

TG Therapeutics (TGTX)TG TherapeuticsEarnings

First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million Raises full year 2026 total global revenue target to approximately $925 million and raises full year 2026 BRIUMVI U.S.

Related news

TGTXTG Therapeutics2026-08-03 11:00 EST

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

TGTXTG Therapeutics2026-02-26 12:00 EST

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

View all latest news

TG Therapeutics

B-Cell-Directed Therapies TG Therapeutics develops and commercializes therapies targeting B cells in multiple sclerosis and other autoimmune diseases. Its portfolio combines an approved anti-CD20 antibody with alternative formulations and an allogeneic cell-therapy program. BRIUMVI BRIUMVI, or ublituximab, is a glycoengineered CD20...

Recent company news

TGTXTG Therapeutics2026-08-03 11:00 EST

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

TGTXTG Therapeutics2026-07-29 11:30 EST

TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update

TGTXTG Therapeutics2026-07-06 11:30 EST

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

TGTXTG Therapeutics2026-06-09 11:30 EST

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

TGTXTG Therapeutics2026-06-03 11:30 EST

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

Stock data

Close
49.55 USD
Market cap
5.61B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States